Drug Profile


Alternative Names: Oracine; VUFB 16956

Latest Information Update: 14 Apr 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VUFB
  • Developer Synthesia; Zentiva
  • Class Antineoplastics; Ethanolamines; Isoquinolines; Small molecules
  • Mechanism of Action DNA inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 15 Sep 2003 Leciva has merged with Slovakofarma to form Zentiva
  • 14 Feb 2002 Profile reviewed and compound appears to be in active development
  • 15 Feb 2001 Phase-II clinical trials for Cancer in Czech Republic (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top